U.S. Markets closed

Health Canada plans to suspend Allergan's breast implant license

April 4 (Reuters) - The Canadian health regulator said on Thursday it was advising Allergan Plc that it plans to suspend the license for the Botox-maker's Biocell breast implants.

Health Canada said its move followed the completion of its assessment of textured breast implants as part of a larger ongoing safety review. (Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel)